{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T17:00:37Z","timestamp":1791478837260,"version":"4.3.4"},"reference-count":13,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003083","name":"European Association of Urology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003083","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.euf.2023.12.002","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T14:23:47Z","timestamp":1704810227000},"page":"662-665","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["The Financial Burden of Guideline-recommended Cancer Medications for Metastatic Urothelial Carcinoma"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7011-0537","authenticated-orcid":false,"given":"Roberto","family":"Contieri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura S.","family":"Mertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Giannatempo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo","family":"Hurle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Alfred","family":"Witjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J.","family":"Ribal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas W.G.","family":"van Rhijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Malavaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2023.12.002_b0005","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.euo.2022.10.003","article-title":"Epidemiology, screening, and prevention of bladder cancer","volume":"5","author":"Lobo","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euf.2023.12.002_b0010","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/bju.14872","article-title":"The natural history of untreated muscle-invasive bladder cancer","volume":"125","author":"Martini","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2023.12.002_b0015","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2023.12.002_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102360","article-title":"Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: a systematic review and meta-analysis","volume":"104","author":"Martini","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.euf.2023.12.002_b0025","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.eururo.2022.08.001","article-title":"A plea for economically sustainable evidence-based guidelines","volume":"82","author":"Martini","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2023.12.002_b0030","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","article-title":"Treatment of patients with metastatic urothelial cancer \u201cunfit\u201d for cisplatin-based chemotherapy","volume":"29","author":"Galsky","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2023.12.002_b0035","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2023.12.002_b0040","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1478-7547-1-8","article-title":"Generalized cost-effectiveness analysis for national-level priority-setting in the health sector","volume":"1","author":"Hutubessy","year":"2003","journal-title":"Cost Eff Resour Alloc"},{"key":"10.1016\/j.euf.2023.12.002_b0045","doi-asserted-by":"crossref","first-page":"e532","DOI":"10.1016\/S1470-2045(22)00705-7","article-title":"US cancer drug prices do not reflect benefits to patients","volume":"23","author":"Furlow","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2023.12.002_b0050","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.3390\/cancers15143654","article-title":"Immunotherapy in urothelial cancer: stop when achieving a response, restart upon disease progression","volume":"15","author":"Salhi","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.euf.2023.12.002_b0055","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1186\/s12885-023-10881-8","article-title":"A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO Protocol study","volume":"23","author":"Gravis","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.euf.2023.12.002_b0060","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S1470-2045(15)00486-6","article-title":"Actual costs of cancer drugs in 15 European countries","volume":"17","author":"van Harten","year":"2016","journal-title":"Lancet Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.euf.2023.12.002_b0065","doi-asserted-by":"crossref","first-page":"S1340","DOI":"10.1016\/j.annonc.2023.10.106","article-title":"LBA6 EV-302\/KEYNOTE-A39: open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la\/mUC)","volume":"34","author":"Powles","year":"2023","journal-title":"Ann Oncol"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456923002924?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456923002924?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T19:35:32Z","timestamp":1732995332000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456923002924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S2405456923002924"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2023.12.002","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Financial Burden of Guideline-recommended Cancer Medications for Metastatic Urothelial Carcinoma","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2023.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}